VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients
Wouter B. Nagengast(University Medical Center Groningen), Geke A.P. Hospers(University Medical Center Groningen), Harald J. Hoekstra(University Medical Center Groningen), Schelto Kruijff(University Medical Center Groningen), Esther M.E. van Straten(University Medical Center Groningen), Wilfred F.A. den Dunnen(University Medical Center Groningen), Elisabeth G.E. de Vries(Karolinska University Hospital), Adrienne H. Brouwers(University Medical Center Groningen), Johan R. de Jong(University Medical Center Groningen), Nanno H. Mulder(University Medical Center Groningen), Harry Hollema(University Medical Center Groningen), Marjolijn N. Lub–de Hooge(University Medical Center Groningen), Rudi Dierckx(University Medical Center Groningen)
Cited by 55
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795